Start-Up Spotlight: Two Pore Guys, Gearing Up To Market Unique Handheld Nanopore Sensor After Inking Agreement With Monsanto

Two Pore Guys has developed a digital, hand-held single-molecule biosensor capable of detecting a wide array of molecules including viruses, bacteria, antibodies and pathogens. The company plans to send the first-generation of the developer kits to strategic partners in mid-2018 and already has inked agreements with human diagnostics, animal health companies and agribusiness giant Monsanto Co.

Start-up Spotlight

Editors' note: This article was updated Dec. 18 to clarify that the company plans to send out the first-generation of its developer kits to strategic partners in mid-2018, but it won't actively be "marketing" the product until an undisclosed later date.

Two Pore Guys Inc.'s top executive claims the company's technology, a digital, hand-held single-molecule biosensor, is capable of detecting molecules of any type – viruses, bacteria, antibodies, pathogens –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Startups & SMEs

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.